



Original Articles

Frequent amplifications of *ESR1*, *ERBB2* and *MDM4* in primary invasive lobular breast carcinoma

Lan Cao^{a,b,c,1}, Ahmed Basudan^{a,c,d,1,2}, Matthew J. Sikora^{a,c,3}, Amir Bahreini^{a,c,4}, Nilgun Tasdemir^{a,c,e}, Kevin M. Levine^{a,c,f}, Rachel C. Jankowitz^{c,g}, Priscilla F. McAuliffe^{a,c,h}, David Dabbsⁱ, Sue Haupt^j, Ygal Haupt^j, Peter C. Lucas^f, Adrian V. Lee^{a,c,d,e}, Steffi Oesterreich^{a,c,e}, Jennifer M. Atkinson^{a,c,e,*}

^a Women's Cancer Research Center, Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, USA

^b Department of Obstetrics and Gynecology, The Third Xiangya Hospital, Central South University, Changsha, China

^c UPMC Hillman Cancer Center, Pittsburgh, PA, USA

^d Department of Human Genetics, University of Pittsburgh, Pittsburgh, PA, USA

^e Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA, USA

^f Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA

^g Department of Medicine, Division of Hematology Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

^h Division of Surgical Oncology, Department of Surgery, Pittsburgh, PA, USA

ⁱ Division of Breast and Gynecologic Pathology, Department of Pathology, Pittsburgh, PA, USA

^j Peter MacCallum Cancer Center, Melbourne, Australia

ARTICLE INFO

Keywords:

ILC
ESR1
ERBB2
MDM4
Amplification

ABSTRACT

Invasive lobular carcinoma (ILC) is the second most common histological subtype of breast cancer following invasive ductal carcinoma (IDC). To identify potential genetic drivers of ILC progression, we used NanoString nCounter technology to investigate the DNA copy number (CN) in 70 well-curated primary ILC samples. We confirmed prior observations of frequent amplification of *CCND1* (33%), and *MYC* (17%) in ILC, but additionally identified a substantial subset of ILCs with *ESR1* and *ERBB2* (19%) amplifications. Of interest, tumors with *ESR1* CN gains (14%) and amplification (10%) were more likely to recur compared to those with normal CN. Finally, we observed that *MDM4* (MDMX) was amplified in 17% of ILC samples. *MDM4* knockdown in TP53 wild-type ILC cell lines caused increased apoptosis, decreased proliferation associated with cell cycle arrest, and concomitant activation of TP53 target genes. Similar effects were seen in TP53 mutant cells, indicating a TP53-independent role for *MDM4* in ILC. To conclude, amplification of *ESR1* and *MDM4* are potential genetic drivers of ILC. These amplifications may represent actionable, targetable tumor dependencies, and thus have potential clinical implications and warrant further study.

1. Introduction

Invasive lobular carcinoma (ILC) represents the second most prevalent histological subtype of breast cancer after invasive ductal carcinoma (IDC), accounting for 10–15% of all invasive breast cancer. It is characterized by small, round cells, invading the adjacent stroma in a

single-file pattern [1]. Although ILC differs from IDC in several histological and clinical features, the same therapies are used to treat patients with ILC and IDC, at least in part due to insufficient knowledge of druggable pathways unique to ILC. Numerous studies have reported mutational and copy number (CN) characterization of breast cancer [2–5]; however, due to low numbers of ILC samples, only limited details

Abbreviations: Amplification, Amp; chromosomal comparative genomic hybridization, CGH; copy number alteration, CNA; deletion, Del; doxycycline, DOX; estradiol, E2; estrogen receptor, ER; invasive ductal carcinoma, IDC; Invasive lobular carcinoma, ILC; knock down, KD; Recurrence free survival, RFS; TP53 mutant, TP53mut; TP53 wild type, TP53 wt

* Corresponding author. University of Pittsburgh, Magee Womens Research Institute, 204 Craft Avenue, Room B406, Pittsburgh, PA, 15213, USA.

¹ Equal contributors.

² Current address: Department of Clinical Laboratory Sciences, King Saud University, Saudi Arabia.

³ Current address: Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

⁴ Current address: Palindrome Co., Isfahan, Iran.

<https://doi.org/10.1016/j.canlet.2019.06.011>

Received 8 April 2019; Received in revised form 2 June 2019; Accepted 17 June 2019

0304-3835/© 2019 Elsevier B.V. All rights reserved.

are available regarding genomic alterations that drive this unique subtype of breast cancer. These studies have uncovered a number of specific differences in the genetic make-up of ILC compared to IDC, including enrichment of *PTEN* loss, *PIK3CA*, *FOXA1*, *ERBB2* and *ERBB3* mutations, in addition to the well described ILC genetic hallmark of *CDH1* loss [6–8]. CN analysis using chromosomal comparative genomic hybridization (CGH) revealed gain of chromosomal regions of 1q and loss of 16p [9–11]. In another study, two of eleven patients with multifocal ILC showed gain in CN at the 11q13.3 locus, which encodes genes such as *CCND1*, *FADD* and *ORAOV1* [12]. Frequent CN amplification at 11q13.3 was further confirmed in a large targeted sequencing study, which additionally revealed high levels of amplification at, 8q24.21 (*MYC*), 15q26.3 (*IGF1R*), and 8p11.23 (*FGFR1*) in ILC [6–8]. Furthermore, gain of chromosomes 1q and 8q and loss of chromosome 11q were found to be more frequent in the hormone-related subtype, which is characterized by active ER/PR signaling and EMT features [13].

A number of studies have recently shown *ESR1* CN amplifications, encoding the estrogen receptor (ER), in ILC [8,14–18]; however, the data are sparse and conflicting, and the clinical relevance remains unclear. While some studies report *ESR1* amplifications at a relatively high rate of ~20%, associated with either improved [14,15] or worse outcomes [16], others have detected a significantly lower *ESR1*-amplification frequency (< 5%) [17,18], possibly due to differences in methodology, sample cohorts, and threshold definitions [19,20]. Intriguingly, Desmedt et al. recently reported *ESR1* amplification in up to 25% of ILC samples [8], a finding that warrants validation in an independent cohort.

To expand upon prior CN analyses in primary ILC, we utilized a highly sensitive NanoString-based approach recently described by us [21]. Herein, we utilized probes covering 67 genes with known roles in breast cancer progression and therapy resistance, including *ESR1*, *CCND1*, *MYC*, *IGF1R*, and *FGFR1*, and comprehensively characterized their CN in 70 primary ILC samples with detailed clinical information. Besides confirming frequent *ESR1* CN gain and amplifications, we also show a significant association with higher risk of subsequent recurrence. Finally, we show, amplification of *MDM4* (*MDMX*) in ILC. While *MDM4* has primarily been described as a negative regulator of TP53 [22], our functional studies revealed an essential role in cell proliferation in both a TP53-dependent and independent manner, justifying further studies on the role of *MDM4* amplification in ILC.

2. Materials and methods

2.1. Retrospective cohort of ILC samples, and DNA and RNA isolation

Following review and approval by the Institutional Review Board at the University of Pittsburgh, we obtained formalin-fixed paraffin-embedded (FFPE) sections from primary ER + ILC cases diagnosed between 1990 and 2011 at UPMC Magee-Women's Hospital. Samples were macrodissected when tumor cellularity < 40%, as previously described [21]. DNA and RNA isolations were performed using the QIAamp DNA FFPE kit (cat#56404) and Qiagen RNeasy FFPE kit (cat#73504) respectively, as per manufacturer's instructions. Isolated DNA and RNA were quantified using the ThermoFisher Qubit dsDNA S/BR kit and Nanodrop Spectrophotometer (ThermoScientific), respectively.

Recurrence free survival (RFS) was measured as the time between date of diagnosis and date of local, regional, or distant recurrence. The median follow-up of patients in our cohort was 15.9 years. The cohort included 18 cases with recurrences (R; 6 local and 12 distant recurrences), and 52 cases that did not recur (non-recurrence, NR). Additional clinicopathological characteristics are shown in [Supplementary Table S1](#) and further cohort details are described in supplemental text.

2.2. Nanostring copy number (CN) and mRNA expression analysis

A total of 70 samples with sufficient DNA (> 150 ng) were used for NanoString nCounter-based CN analysis. The development of the NanoString CN library, the overall methodological approach, and extensive quality control (QC) have been recently described by us [21]. Briefly, we designed 100bp DNA hybridization probes for a total of 67 genes known to be frequently altered in breast cancer. Given prior evidence for *ESR1* amplifications in ILC we used 10 probes to cover the *ESR1* gene, and 2–3 probes for the other 66 genes. *ESR1* CN increase by 35% (CN ≥ 2.7) and decrease by 50% (CN ≤ 1) were considered gains/amplifications and deletions, respectively. CN calls above ≥ 10 were considered high amplifications. Given the lower resolution for other genes in the panel, we used one CN cutoff of ≥ 5 as amplification. Detailed CN calls for all genes in tumor samples and cell lines are provided in [Tables S2 and S3](#), respectively. The Complex Heatmap R package was used to generate oncoprints for CN alterations (CNA). A tile plot was generated in R using the ggplot2 package. To correlate CN levels of genes of interest with expression, several probes covering *ESR1*, *CCND1*, *ERBB2*, *MDM4* and *MYC* were used to determine expression in corresponding RNA samples from the same patients also using the Nanostring nCounter platform as we previously described [23].

2.3. Quantitative real time polymerase chain reaction (qRT-PCR)

mRNA from triplicate tumor samples was isolated as per manufacturer's protocols using Qiagen RNeasy Mini Kit and quantified by NanoDrop. 500 ng of mRNA per sample was converted to cDNA, using 1X iScript (BioRad#1708891) or 1X PrimeScript (Takara #RR036B) as per manufacturer's protocol. Gene expression was assessed by qRT-PCR using SsoAdvanced™ Universal SYBR® Green Supermix (BioRad#1725274) and primers listed in [Table S4](#), assaying RPLP0 as a housekeeping gene.

2.4. Cell line culture

MCF-7, MCF-10A, MDA-MB-134-VI (MM134), MDA-MB-330 (MM330), and HEK293T cells were obtained from ATCC. Sum44PE cells were purchased from Asterand. BCK4 cells were a generous gift from Britta Jacobsen, PhD (University of Colorado Anschutz Medical Campus) and recently described [24,25]. Media formulations for cell culture are outlined in the supplemental text. Cells were periodically confirmed to be mycoplasma negative, authenticated at the University of Arizona Genetics Core by Short Tandem Repeat (STR) profiling and kept in continuous culture for less than 6 months. To assay TP53 status in cell lines, PCR was performed on cDNA (primers listed in [Table S4](#)) covering the full length *TP53* transcript using Gotaq DNA Polymerase (Promega# M3001) as per manufacturer's protocol. Sequenced PCR products were blasted against the human reference *TP53* sequences (NM_000546).

2.5. Modulation of *MDM4* expression

For overexpression studies, cells were reverse transfected with pIRES1neo empty vector or *MDM4* cDNA overexpression plasmid (a gift from Wei Gu, PhD; Columbia University) using Lipofectamine™ 3000 (Thermo Fisher Scientific#L3000015), according to the manufacturer's protocol. Stably transfected cells were selected using 1 mg/ml G418. For transient knockdown studies, cells were reverse transfected with ON-TARGETplus Non-targeting Pool (Dharmacon#D-001810-10-05) or SMARTpool ON-TARGETplus Human *MDM4* siRNA (Dharmacon#L-006536-02-0005) using Lipofectamine™ RNAiMAX and Opti-MEM® I (Gibco#31985-070) and following the manufacturer's protocol (Thermo Fisher Scientific#13778-150). For stable knockdown studies, *MDM4* shRNA (shMDM4#1 targeting exon 6 and shMDM4#2 targeting

the 3' UTR) and control shRNA (shCTL) in the doxycycline (Dox) inducible GFP-tagged lentiviral vector FH1t (provided by Ygal Haupt, PhD; Peter MacCallum Cancer Center, Australia), along with an additional non-targeting Renilla shRNA (empty vector provided by Dr Marco Herold; University of Melbourne, Australia) were used. shRNA sequences are listed in Table S4. Viruses were generated by transfecting HEK293T cells using third generation packaging systems and polyethylenimine (PEI) (1 µg/mL; Polysciences#23966–2) with a 3:1 ratio of PEI to transfected DNA constructs. shPASHA (targeting human DGCR8) was used to increase titer as previously described [26]. Virus was collected at the 36- and 48-h time points, filtered through 0.45 µm filters (Fisher#09-754-21), and treated with 1 µg/mL Polybrene (Sigma#107689-10G) to infect target cells. Cells were infected twice and allowed to recover for three days prior to sorting for GFP positive cells (~40–50%) by FACS. shRNA expression was induced by treatment with 200 ng/mL and 160 ng/mL DOX in BCK4 and SUM44PE cells, respectively, with replenishment every 3–4 days.

2.6. Proliferation and colony formation assay

Cell proliferation was assessed either by FluoReporter™ Blue Fluorometric dsDNA Quantitation Kit (Invitrogen#F2962) or IncuCyte® Live-Cell Imaging System (Essen BioScience) according to manufacturer's recommendations. Cells were plated in technical replicates (n = 4–6) at 15,000 (ILC) or 5000 (IDC) cells/well in 96-well plates. Data was captured on a PerkinElmer plate reader (Victor). Alternatively, cells were monitored on the IncuCyte Live Cell Analysis Imaging System using integrated confluence as a surrogate for cell number. Relative fold change in growth/confluence was normalized to day 0 data.

For colony formation assays, 15,000 cells were seeded in 6 well-plates and treated with DOX next day. After 18 days, cells were fixed with 100% methanol for 10 min and stained with 0.5% crystal violet solution in 25% methanol for 10 min, followed by gently rinsing with distilled water and drying at room temperature. Plates were imaged on an SZX16 dissecting microscope with a Nikon camera under bright field illumination at 0.8X magnification. Colony confluency fractions were counted using cellSens Dimension (Olympus) software.

2.7. Flow cytometry assays

For cell cycle analysis, cells were collected by trypsinization, diluted to 1×10^6 cells/mL and stained with 20 µg/mL Hoechst 33342 (Life Technologies#H3570) for 30 min at 37 °C in the dark.

For the apoptosis assay, cells were collected and washed with PBS, and re-suspended in 1X Annexin V binding buffer (BD Biosciences#556454) at a dilution of 1×10^6 cells/mL. 100 µl of cell suspension was stained with Propidium Iodide (PI; BD biosciences#556463) and APC Annexin V (BD biosciences#561012) at room temperature for 15 min as per the manufacturer's protocol. Samples were acquired on a LSR II Flow Cytometer using compensation and analyzed using FACSDiva (BD Biosciences).

2.8. Immunoblotting (IB)

Proteins were extracted using RIPA buffer supplemented with 1X Halt Protease Inhibitor Cocktail. 25–50 µg per sample was run on 9% or 15% gradient SDS-PAGE gels and transferred to PVDF membranes (Millipore#IPFL00010), and blocked using Odyssey PBS blocking buffer (LiCor#927–40000) and incubated with the following antibodies: TP53 (1:500; sc-6243, Santa Cruz Biotechnology), MDM4 (1:500; A300-287A, Bethyl Laboratories), P21 (1:200; sc-397, Santa Cruz Biotechnology), PUMA (1:500; D30C10, Cell Signaling Technology), BAX (1:500; D2E11, Cell Signaling Technology), Tubulin gamma (1:10,000; ab11317, Abcam), ER (1:1000; 6F11, Leica Biosystems) and secondary antibodies anti-mouse 800CW:

Table 1
Clinical characterization of ILC primary tumors cohort.

	Patients without recurrence (N = 52)	Patients with recurrence (N = 18)	p value
Median age	60.5	60	0.37
Pathologic stage			0.009
I	15(28.8%)	1(5.6%)	
II	27(51.9%)	10(55.5%)	
III	6(11.5%)	6(33.3%)	
NA	4(7.7%)	1(5.6%)	
Pathologic grade			0.77
G1	11(21.2%)	4(22.2%)	
G2	28(53.8%)	9(50.0%)	
G3	3(5.8%)	2(11.1%)	
NA	10(19.2%)	3(16.7%)	
ER (IHC)			
Positive	52(100%)	18(100%)	
Average ER H-score ^a	237.6	214.1	0.24
PR (IHC)			
positive	47(90.4%)	17(94.4%)	> 0.99
negative	5(9.6)	1(5.6%)	
Average PR H-score ^b	170.6	112.7	0.076
HER2 (IHC)			> 0.99
Positive	2(3.8%)	1(5.6%)	
Negative	46(88.5%)	16(88.9%)	

NA, not available; ER, estrogen receptor; PR, progesterone receptor.

^a 41 samples of non-recurrence tumors and 12 samples of recurrence tumors were available for ER histological scores.

^b 40 samples of non-recurrence tumors and 11 samples of recurrence tumors were available for PR histological scores.

LiCor#925–32210, anti-rabbit 800CW; LiCor#925–32211. Blots were imaged using the Odyssey Infrared Imaging system (LiCor).

3. Results

3.1. Frequent *ESR1* amplifications in ILC and association with increased risk of recurrence

To identify potential genetic drivers of ILC progression, we performed CN analysis on 70 ER + primary ILC tumors (Table 1) and initially focused on *ESR1* CN alterations (Fig. 1A). Based on average calls from probes covering the promoter region, two non-coding exons, and seven coding exons, we detected ~24% of samples with *ESR1* gains (CN 2.7–10; 10 tumors; 14% of samples) or amplifications (CN ≥ 10; 7 tumors; 14% of samples). Tumors with elevated *ESR1* CN levels showed significantly higher mRNA expression compared to the group with normal CNs (Fig. 1B, p value = 0.001). ER histological scores (H-scores) were available for a subset of 53 samples, which were slightly higher in the group with *ESR1* gains and amplifications; though did not reach statistical significance (Fig. S1A). An analysis on a case-by-case basis shows that samples #197 and #54 (with consistent CNAs across the exons; shown on the very left in Fig. 1A) display some of the highest levels of *ESR1* mRNA and ER protein expression in our cohort (Supplementary Table S5).

To determine whether *ESR1* CN alterations were associated with clinical outcome, we compared groups with (n = 18) or without recurrence (n = 52) (Table 1). 39% (n = 7) of samples from patients that recurred (R) showed *ESR1* gain or amplification while only 19% (n = 10) of the non-recurrent group (NR) presented with gain or amplification (Fig. 1C) (p = 0.047).

Recurrence-free survival (RFS) data was also available for 67/70 patients. As expected, CN gains or amplifications showed a trend towards a worse RFS outcome, although this failed to reach statistical significance (Fig. S1B, p value = 0.2), potentially due to our limited sample size.




Fig. 1. Frequent ESR1 copy number alterations in 70 primary ER positive ILC specimens. A. OncoPrint visualization of ESR1 CN alterations in primary ER positive ILC. Levels of amplification and deletion are color-coded. Each column represents a single sample. Each row indicates the copy number call of the corresponding single exon probe. Frequencies of alterations are indicated to the left side of each row. Samples with subsequent recurrences are annotated with ‘*’ symbol. E01-E10: exons 1–10. Untranslated exons (E1 and E2) are annotated with ‘#’ symbol. P: Promoter probe. ESR1_ave: average copy number call of all probes. B. Box plot comparison of ESR1 mRNA expression measured by NanoString between normal and gain/amplified samples (Wilcoxon rank-sum test). C. Frequency of ESR1 CN amplifications for the non-recurrence (NR) and recurrence groups (R) (Chi-square test, one-side, p = 0.0468). Numbers show the count of tumors for each group. Amp: amplification. Del: deletion.

Overall, these results demonstrate that primary ILC exhibit frequent ESR1 gains and amplifications, which are significant enriched in samples with subsequent recurrence, suggesting a potential role for ESR1 CN gains/amplifications in endocrine resistance.

3.2. Enrichment of CCND1, ERBB2, MDM4 and MYC amplifications in ILC

In addition to ESR1, the NanoString library also contained probes covering 66 genes that were previously implicated in breast cancer progression (Table S2, and Material and Methods). The most frequently amplified genes from this CN analysis are shown in Fig. 2A. Deletions were rare (Fig. S2), with the most frequently deleted gene (NCOR2) being lost in 5 samples. Genes with the highest frequency of amplification included CCND1(33%), ERBB2 (19%), MDM4 (17%), and MYC (17%). The amplification events were significantly correlated with mRNA expression for CCND1, and MDM4, along with a trend for ERBB2 but not MYC (Fig. 2B). We observed some associations between amplifications of CCND1, FGF19, FADD, AAMDC, PAK1 and CTTN as was expected given these genes map to the well described 11q13 amplicon [27,28]. Due to low numbers, we did not perform a formal statistical co-occurrence test.

In summary, the NanoString analysis confirmed prior observations

of frequent amplification of 11q13, including CCND1, but also identified a higher than expected rate of ERBB2 amplification as well as novel MDM4 amplifications.

3.3. Association of MDM4 amplification with TP53 status in primary ILC and ILC cell models

Despite not observing a significant association between MDM4 amplification and recurrence free survival in our cohort (Fig. S3), we decided to explore a potential role for MDM4 as a driver of ILC progression due to the high frequency of MDM4 amplifications (12/70). Since MDM4 was initially discovered as a TP53 regulator that possesses significant homology to MDM2²², most studies on MDM4 have focused on its TP53-dependent role. In line with this, MDM4 amplification and/or overexpression is more frequent in tumors that retain wild type TP53 (wt TP53) [29]. We performed sanger sequencing of TP53 in eight tumors with MDM4 amplification, and determined a wt TP53 status in all sequenced samples, in line with the low TP53 mutation frequency seen in primary TCGA ILC tumors (~7%) [30].

To further elucidate the role of MDM4 in ILC, we selected a set of ILC cell lines and measured MDM4 CN, RNA expression and protein levels (Figs. S4A–C). The IDC cell line MCF-7 harboring a previously





Fig. 2. CCND1, ERBB2, MDM4 and MYC are the most frequently amplified genes in ER positive primary ILC. A. Oncoprint visualization of CN amplifications by genes (rows) and samples (columns). Frequencies of the amplifications are indicated to the left side of each row. Samples with later recurrence are annotated with ‘*’ symbol. B. Comparison of NanoString mRNA expression of most frequently amplified genes in the ILC cohort between amplified and non-amplified samples (Wilcoxon rank-sum test). Amp: amplification.

described MDM4 amplification [31] was included as a positive control and data were normalized to normal breast tissue. In ILC cell lines, we observed MDM4 CN gain in MM134 and BCK4; however, MM134 showed low MDM4 expression compared to the overexpression in BCK4

and the positive control. The TP53 status of ILC cell lines has previously been described [32], and also further verified by us using Sanger sequencing. BCK4 cells express relatively high MDM4 and harbor a single nucleotide polymorphism (SNP) in codon 72 of *TP53* (RS1042522), a




Fig. 3. Targeting MDM4 in p53-functional breast cancer cell line BCK4 suppresses cell growth by inducing G0/G1 arrest and apoptosis. A. Growth curves of BCK4 cells transiently transfected with siMDM4 vs siCTL (two-way ANOVA, $***p < 0.001$, $n = 2$). MDM4 transient KD was confirmed by immunoblots shown top left. B. shRNA KD in BCK4 cells confirmed by immunoblot. DOX: doxycycline. C. Representative images from colony formation assays of BCK4 shCTL and shMDM4 cells. Quantifications of normalized confluency are shown below (data represent the average of biological triplicates \pm SD; t -tests, $***p < 0.001$, $n = 2$). D. Representative FACS figures of cell cycle analysis of siCTL and siMDM4 after knockdown for 4 days. E. Percentage of cells in G0/G1 phase in BCK4 siCTL vs siMDM4 after transfection for 4 days (t -tests, data represent the average of 8 biological replicates from three independent experiments \pm SD). F. Apoptosis assay profiles in BCK4 cells transfected with siCTL or siMDM4 after 4 days (p value by t -test for total apoptotic cells in siCTL vs siMDM4, $***p < 0.001$, $n = 3$). G. qPCR of p53 downstream targets in BCK4 cells after MDM4 downregulation (Data represent the average of biological triplicates \pm SD; t -tests, $**p < 0.05$, $***p < 0.001$). H. Immunoblots demonstrating induction of p53 target genes in BCK4 cells after MDM4 downregulation by siRNA.

common SNP. MM134 and MM330 cells harbor *TP53* E285K and Y220C mutations, respectively, both of which were reported as loss-of-function changes in the IARC TP53 database (<http://p53.iarc.fr/>). A truncating *TP53* frameshift mutation (82_84delinsCA, pE28fsX16) was found in Sum44PE cells, which was also reported in the IARC database. Based on this sequencing information, we selected BCK4 cells as our primary ILC model of functional TP53 in our subsequent studies, while including MM134, Sum44PE and MM330 as TP53 mutant models.

3.4. Targeting MDM4 in the wildtype TP53 breast cancer cell line BCK4 suppresses cell growth by inducing G0/G1 arrest and apoptosis

Based on the observation of MDM4 overexpression in BCK4 cells

(Figs. S4B and C), we performed transient siRNA-mediated *MDM4* inhibition studies. We confirmed MDM4 knock-down (KD) at the protein level by immunoblot and observed a significant impact on cell growth/survival over 7 days compared to a control siRNA (Fig. 3A). In addition, we tested the effect of MDM4 KD in the wt TP53 IDC cell line MCF7 and observed a similar growth inhibitory effect (Fig. S4F). In addition to transient experiments, the ability of MDM4 KD to decrease cell proliferation in BCK4 cells was also seen by lentiviral-mediated doxycycline (DOX)-inducible shRNAs (verified by immunoblot in Fig. 3B) in both a growth assay (Fig. S5A) and a colony formation assay (Fig. 3C). Furthermore, we performed cell cycle and apoptosis assays in consideration of the well-known role of MDM4 in regulating TP53. Cell cycle analysis revealed a reproducible and significantly increased G0/

G1 arrest after MDM4 KD for 4 days (Fig. 3D and E). In addition to reduced proliferation, we also observed an increase in apoptosis in cells transfected with siMDM4 relative to siCTL, as determined by FACS analysis (Fig. 3F).

To understand the downstream effects of MDM4 silencing in BCK4 cells, we assessed RNA and protein levels of TP53 and its known targets (Fig. 3G and H). MDM4 siRNA KD in BCK4 cells did not alter TP53 expression at the protein level but did induce the pro-apoptotic Bcl-2 family members PUMA and BAX, and cell cycle inhibitor p21 at both the RNA and protein levels. These results are consistent with previous studies of MDM4 KD in TP53 wt cell lines from breast cancer [33] and other cancers [34]. Combined, this data shows that MDM4 expression in the wt TP53 ILC cell line BCK4 contributes to cell cycle progression and that its oncogenic role is predominantly achieved by inhibition of TP53 downstream transactivation.

3.5. MDM4 promotes cell cycle progression in mutant TP53 ILC cell lines

To further investigate if the proliferative role of MDM4 is dependent on functional TP53, we employed MDM4 KD studies in MM330, MM134 and Sum44PE ILC cell lines harboring TP53 mutations. MDM4 depletion suppressed cell growth by more than 50% in the Sum44PE cell line (Fig. 4A) in a 7-day growth assay. In addition, we also knocked down MDM4 using dox-inducible shRNAs in Sum44PE cells (Fig. 4B) and observed a similar inhibitory effect in both growth (Fig. S5), and colony formation assays (Fig. 4C). Interestingly, this MDM4 KD induced growth inhibition phenotype was cell line-dependent as we did not observe comparable changes in growth rates of the other two TP53mut ILC cell lines, MM330 (Fig. S4D) and MM134 (Fig. 4A), while seeing effects in the TP53mut IDC cell line T47D (Fig. S4H). We next performed FACS-based cell cycle and apoptosis assays on Sum44PE cells and observed a significant increase in G0/G1 arrest (Fig. 4D) and apoptosis (Fig. 4E) following MDM4 downregulation by siRNA. As expected, qPCR and immunoblot analyses did not reveal an induction of TP53 downstream targets (Fig. S6A), as was seen in the TP53 wt cell line BCK4 (see Fig. 3G and H), consistent with inactive TP53 signaling.

To further confirm the proliferative role of MDM4 in TP53mut ILC cells, we constitutively overexpressed MDM4 in both MM134 and Sum44PE cells (Fig. 4F). We detected a mild but reproducible and significant increase in proliferation in a 6-day growth assay for MM134 but not in Sum44PE cells (Figs. S6B and C), with similar results from long-term colony formation assays (Fig. 4G and H). Consistent with our earlier data (see Fig. S6A), we did not observe downregulation of PUMA, p21 and BAX in MDM4-overexpressing cells (Fig. S6D).

Combined, our data suggests that MDM4 KD results in context-dependent suppression of cell proliferation via delaying cell cycle progression and inducing apoptosis through both TP53-dependent and independent mechanisms.

4. Discussion

There is increasing realization that development and progression of ILC is associated with unique pathological, clinical, and molecular features. The goal of further deciphering molecular underpinnings of ILC is to personalize treatment and improve outcome for patients. In our CNA study in ILC, we made a number of novel observations with potential clinical implications, including (1) frequent *ESR1* CN gain (14%) or amplification (10%) associated with disease recurrence, (2) frequent *ERBB2* amplification (19%), and (3) frequent *MDM4* amplifications (17%) and a functional role for MDM4 in ILC. In addition, we were able to confirm previously reported amplifications at 11q13 (*CCND1*, 33%) and 8q24 (*MYC*, 17%) [7,8,35].

Our CN characterization of ILC revealed frequent *ESR1* amplifications in about one quarter of cases (24%), associated with significantly higher mRNA expression. Importantly, *ESR1* amplifications were significantly enriched in samples from patients with subsequent

recurrences. Our findings are in agreement with the recently reported study detailing *ESR1* amplifications in 25% of primary ILC, association with mRNA expression, and enrichment in aggressive ILC tumors by Desmedt et al. [8]. In that study, the alterations were significantly enriched in ILC versus IDC, suggesting a unique role for amplified *ESR1* in modulating response to estradiol and endocrine therapy in tumors lacking functional E-cadherin. Collectively, these findings justify further clinical investigation of ILC in the context of endocrine therapies, especially with respect to estradiol-containing therapy regimens as previously described by us and others [36–39].

Beyond *ESR1*, we also observed *ERBB2* amplifications in 19% of cases. Given the growing evidence for increased rates of HER2/HER3 mutations in ILC [6,8], the finding of higher rates of *ERBB2* amplification is of potential interest. Of note, many of these *ERBB2* amplified cases were designated as HER2 negative by prior clinical IHC/fluorescence in situ hybridization (FISH) testing. This discrepancy could result from tissue heterogeneity, but could also reflect low level amplifications detected by sensitive Nanostring technologies that do not cause high level overexpression. Such low-level gene amplifications might reflect genomic instability, and might not be consequential with regard to the biological consequence of overexpression of the gene that has undergone CN changes. An example for complex structural genomic rearrangement in the absence of high level amplification are the recently reported segmental tandem duplications in breast cancer [40,41]. Additional studies are necessary to further differentiate between CN changes identified with the sensitive Nanostring approach that are associated with true oncogenic driver functions, and those more associated with genetic instability.

In addition to *ESR1* and *ERBB2*, we also observed *MDM4* amplifications in 17% of our primary ILC cases. Previous studies have identified varying rates of *MDM4* amplification in breast cancer, with studies using FISH suggesting a low frequency (< 5%) [31,33]. *MDM4* is amplified in about 13% of all TCGA breast cancers and 18% in ILC cases specifically [30]. *MDM4* amplification has previously been implicated in breast cancer metastasis from genomic evolution analyses among paired primary and metastatic tumors. Here *MDM4* amplification was shown to be associated with endocrine resistance, while *TP53* driver mutations were predominantly early events during metastatic evolution [42,43]. Subsequent gain of *MDM4* in the absence of wt TP53 suggests that MDM4 may have broader functions beyond TP53 transactivation, which is further supported by our current data. Previously, downregulation of *MDM4* mRNA using RNAi *in vitro* and *in vivo* was shown to attenuate both wt TP53 and mutant TP53 breast cancer cell growth [33,44]; however, little is known about the role of MDM4 specifically in ILC. Our data suggests that in the wt TP53 ILC cell line BCK4, the oncogenic role of MDM4 is likely achieved by inhibition of TP53 transactivation. Conversely, in the ILC cell line Sum44PE, with truncated TP53, MDM4 knockdown led to a reproducible and significant induction of G0/G1 arrest and an increase in apoptotic cell death, further supporting the growing literature that MDM4 has TP53 independent roles. However, using the TP53mut ILC cell line MM134 we observed no effect of MDM4 KD, while we did detect a minor growth advantage in MDM4 overexpressing cells in a colony formation assay. The role of MDM4 mediated proliferation in mutant TP53 cells remains unclear, and our data indicates that this may also be cell line dependent. While studies focusing on the TP53-independent functions of MDM4 are limited, data so far indicated that MDM4 interacts with p21, E2F1, p300, ER and p27 independent of TP53 [45–47]. It will be of interest to understand this mechanism in ILC cells lacking functional E-cadherin.

Our data suggests that MDM4 overexpression in wt TP53 primary ILC tumors may reduce apoptosis, enhance progression through the cell cycle and ultimately contribute to tumor proliferation, implicating it as a novel therapeutic target. The development of small molecules that can target the interaction of TP53 and MDM4 and induce a TP53-dependent cell cycle arrest and/or apoptosis have previously been described [48]; however, it remains largely unclear whether blocking the binding of




Fig. 4. MDM4 promotes cell cycle progression in mutant TP53 breast cancer cell lines. A. Growth curves of Sum44PE (left) and MM134 (right) cells transiently transfected with siMDM4 vs siCTL (two-way ANOVA, $***p < 0.001$, ns: no significance, $n = 4$). MDM4 knockdown was confirmed by immunoblots shown top left. B. shRNA KD in Sum44PE cells was confirmed by immunoblot. C. Representative images from colony formation assay in Sum44PE shRen and shMDM4 cells. Quantification of normalized confluency are shown below (data represent the average of biological triplicates \pm SD; t -tests, $***p < 0.001$, $n = 2$). D. Percentage of cells in G0/G1 phase in Sum44PE siCTL vs siMDM4 after transfection for 4 days (t -tests, data represent the average of 6 biological replicates from two independent experiments \pm SD). E. Apoptosis assay profiles in Sum44PE cells transfected with siCTL or siMDM4 after 4 days (p value by t -test for total apoptotic cells in siCTL vs siMDM4, $***p < 0.001$, $n = 2$). F. Immunoblot validation of constitutive MDM4 overexpression in MM134 (left) and Sum44PE (right) cells. G. Representative images of MM134 (left) and Sum44PE (right) cells transfected with EV (empty vector) and OEX (MDM4 overexpression plasmid) after 18-days growth in a colony formation assay. H. Quantifications by area fraction of all the colonies in MM134 (left) and Sum44PE (right) (t -tests, $***p < 0.001$, $n \geq 2$).

MDM proteins to TP53 compromises their TP53-independent functions. While no such agents are currently in clinical development, small molecules specifically targeting the function of MDM4 could potentially hold promise for a subgroup of ILC patients in the future. Given the high frequency of MDM4 CN alterations in ILC reported herein, it will be important to determine the value of such targeted agents and their potential combination with endocrine therapy for ILC patients with MDM4 CNA.

In conclusion, our CNA study of 70 primary ILC specimens has revealed clinically relevant gains and amplifications in *ESR1*, that are associated with disease recurrence, frequent *ERBB2* amplifications often in the absence of clinical IHC scores, and frequent *MDM4* amplifications. Further, our functional studies suggest that MDM4 may contribute to ILC progression through both TP53-dependent and independent mechanisms. We believe our findings provide a molecular foundation to further explore the development and progression of ILC, ultimately providing vital insights that may lead to personalized treatment for patients with this understudied subtype of breast cancer.

Conflicts of interest

The authors declare they have no conflicts of interest with the contents of this article.

Funding

The work is in part funded by the Third Xiangya Hospital, Central South University, a Shear Family Foundation grant, Susan G. Komen Leadership grants to SO (SAC160073) and AVL (SAC110021), and Breast Cancer Research Foundation grants to SO and AVL. MJS is supported by an NIH Pathway to Independence Award (K99CA193734), and NT is supported by a Department of Defense Breakthrough Fellowship (BC160764). SO and AVL are Hillman Foundation Fellows. This project used the UPMC Hillman Cancer Center and Tissue and Research Pathology/Pitt Biospecimen Core shared resource which is supported in part by award P30CA047904.

CRedit authorship contribution statement

Lan Cao: Formal analysis, Writing - original draft. **Ahmed Basudan:** Formal analysis, Writing - original draft. **Matthew J. Sikora:** Formal analysis. **Amir Bahreini:** Formal analysis. **Nilgun Tasdemir:** Formal analysis. **Kevin M. Levine:** Formal analysis. **Rachel C. Jankowitz:** Supervision. **Priscilla F. McAuliffe:** Supervision. **David Dabbs:** Supervision. **Sue Haupt:** Resources, Methodology, Writing - review & editing. **Ygal Haupt:** Resources, Methodology, Writing - review & editing. **Peter C. Lucas:** Supervision. **Adrian V. Lee:** Conceptualization, Supervision, Investigation. **Steffi Oesterreich:** Conceptualization, Supervision, Investigation. **Jennifer M. Atkinson:** Supervision, Investigation, Writing - original draft.

Acknowledgments

We acknowledge Dr. Marco Herold (The Walter and Eliza Hall Institute of Medical Research) for kindly providing the FH1tUTG vector, and Dr. Wei Gu (Columbia University) for the gift of pIRES1neo empty vector and MDM4 (cDNA) overexpression plasmid. We are grateful to Britta Jacobsen, PhD (University of Colorado Denver), for providing the BCK4 cell line. We also thank the UPMC Hillman Cancer Center Biostatistics Core.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.canlet.2019.06.011>.

References

- [1] V. Martinez, J.G. Azopardi, Invasive lobular carcinoma of the breast: incidence and variants, *Histopathology* 3 (6) (1979) 467–488.
- [2] R. Goncalves, W.A. Warner, J. Luo, M.J. Ellis, New concepts in breast cancer genomics and genetics, *Breast Cancer Res.* 16 (1) (2014) 460.
- [3] C.M. Perou, T. Sorlie, M.B. Eisen, M. Van De Rijn, S.S. Jeffrey, C.A. Res, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, Ø. Fluge, A. Pergammenschikov, C. Williams, S.X. Zhu, P.E. Lønning, A.L. Børresen-Dale, P.O. Brown, D. Botstein, Molecular portraits of human breast tumours, *Nature* 406 (6797) (2000) 747–752.
- [4] Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours, *Nature* 490 (7418) (2012) 61–70.
- [5] F. Andre, B. Job, P. Dessen, A. Tordai, S. Michiels, C. Liedtke, C. Richon, K. Yan, B. Wang, G. Vassal, S. Delalogue, G.N. Hortobagyi, W.F. Symmans, V. Lazar, L. Pusztai, Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array, *Clin. Cancer Res.* 15 (2) (2009) 441–451.
- [6] J.S. Ross, K. Wang, C.E. Sheehan, A.B. Boguniewicz, G. Otto, S.R. Downing, J. Sun, J. He, J.A. Curran, S. Ali, R. Yelensky, D. Lipson, G. Palmer, V.A. Miller, P.J. Stephens, Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations, *Clin. Cancer Res.* 19 (10) (2013) 2668–2676.
- [7] G. Ciriello, M.L. Gatzka, A.H. Beck, M.D. Wilkerson, S.K. Rhie, A. Pastore, H. Zhang, M. McLellan, C. Yau, C. Kandoth, R. Bowlby, H. Shen, S. Hayat, R. Fieldhouse, S.C. Lester, G.M.K. Tse, R.E. Factor, L.C. Collins, K.H. Allison, et al., Comprehensive molecular portraits of invasive lobular breast cancer, *Cell* 163 (2) (2015) 506–519.
- [8] C. Desmedt, G. Zoppoli, G. Gundem, G. Pruneri, D. Larsimont, M. Fornili, D. Fumagalli, D. Brown, F. Rothé, D. Vincent, N. Kheddoumi, G. Rouas, S. Majjaj, S. Brohée, P. Van Loo, P. Maisonneuve, R. Salgado, T. Van Brussel, D. Lambrechts, et al., Genomic characterization of primary invasive lobular breast cancer, *J. Clin. Oncol.* 34 (16) (2016) 1872–1880.
- [9] P.T. Simpson, J.S. Reis-Filho, M.B.K. Lambros, C. Jones, D. Steele, A. Mackay, M. Iravani, K. Fenwick, T. Dexter, A. Jones, L. Reid, L. Da Silva, S.J. Shin, D. Hardisson, A. Ashworth, F.C. Schmitt, J. Palacios, S.R. Lakhani, Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas, *J. Pathol.* 215 (3) (2008) 231–244.
- [10] D.E. Stange, B. Radlwimmer, F. Schubert, F. Traub, A. Pich, G. Toedt, F. Mendrzyk, U. Lehmann, R. Eils, H. Kreipe, P. Lichter, High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer, *Clin. Cancer Res.* 12 (2) (2006) 345–352.
- [11] T. Nishizaki, K. Chew, L. Chu, J. Isola, A. Kallioniemi, N. Weidner, F.M. Waldman, Genetic alterations in lobular breast cancer by comparative genomic hybridization, *Int. J. Cancer* 74 (5) (1997) 513–517 <http://www.ncbi.nlm.nih.gov/pubmed/9355973>, Accessed date: 8 January 2019.
- [12] N. Norton, P.P. Advani, D.J. Serie, X.J. Geiger, B.M. Necela, B.C. Axenfeld, J.M. Kachergus, R.W. Feathers, J.M. Carr, J.E. Crook, A. Moreno-Aspitia, P.Z. Anastasiadis, E.A. Perez, E.A. Thompson, Assessment of tumor heterogeneity, as evidenced by gene expression profiles, pathway activation, and gene copy number, in patients with multifocal invasive lobular breast tumors, *PLoS One* 11 (4) (2016).
- [13] M. Michaut, S.F. Chin, I. Majewski, T.M. Severson, T. Bismeyer, L. De Koning, J.K. Peeters, P.C. Schouten, O.M. Rueda, A.J. Bosma, F. Tarrant, Y. Fan, B. He, Z. Xue, L. Mitterpergher, R.J.C. Kluijn, J. Heijmans, M. Snel, B. Pereira, et al., Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer, *Sci. Rep.* 6 (1) (2016) 18517.
- [14] F. Holst, P.R. Stahl, C. Ruiz, O. Hellwinkel, Z. Jehan, M. Wendland, A. Lebeau, L. Terracciano, K. Al-Kuraya, F. Jänicke, G. Sauter, R. Simon, Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer, *Nat. Genet.* 39 (5) (2007) 655–660.
- [15] S. Tomita, Z. Zhang, M. Nakano, M. Ibusuki, T. Kawazoe, Y. Yamamoto, H. Iwase, Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients, *Cancer Sci.* 100 (6) (2009) 1012–1017.
- [16] K.V. Nielsen, B. Ejlersen, S. Müller, S. Møller, B.B. Rasmussen, E. Balslev, A.-V. Lankholm, P. Christiansen, H.T. Mouridsen, Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer, *Breast Canc. Res. Treat.* 127 (2) (2011) 345–355.
- [17] C.B. Moelans, H.N. Monsuur, J.H. de Pinth, R.D. Radersma, R.A. de Weger, P.J. van Diest, ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study, *Anal. Cell Pathol.* 33 (1) (2010) 13–18.
- [18] F. Holst, P. Stahl, O. Hellwinkel, A.M. Dancau, A. Krohn, L. Wuth, C. Heupel, A. Lebeau, L. Terracciano, K. Al-Kuraya, F. Jänicke, G. Sauter, R. Simon, Reply to “ESR1 gene amplification in breast cancer: a common phenomenon?” *Nat. Genet.* 40 (7) (2008) 810–812.
- [19] D.R. Robinson, Y.M. Wu, P. Vats, F. Su, R.J. Lonigro, X. Cao, S. Kalyana-Sundaram, R. Wang, Y. Ning, L. Hodges, A. Gursky, J. Siddiqui, S.A. Tomlins, S. Roychowdhury, K.J. Pienta, S.Y. Kim, J.S. Roberts, J.M. Rae, C.H. Van Poznak, et al., Activating ESR1 mutations in hormone-resistant metastatic breast cancer, *Nat. Genet.* 45 (12) (2013) 1446–1451.
- [20] F. Holst, Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate, *World J. Clin. Oncol.* 7 (2) (2016) 160.
- [21] A. Basudan, N. Priedigkeit, R.J. Hartmaier, E.S. Sokol, A. Bahreini, R.J. Watters, M.M. Boisen, R. Bhargava, K.R. Weiss, M.M. Karsten, C. Denkert, J.-U. Blohmer, J.P. Leone, R.L. Hamilton, A.M. Brufsky, E. Elishaev, P.C. Lucas, A.V. Lee, S. Oesterreich, Frequent ESR1 and CDK pathway copy number alterations in metastatic breast cancer, *Mol. Cancer Res.* 17 (2) (2019) 457–468.
- [22] A. Shvarts, W.T. Steegenga, N. Riteco, T. van Laar, P. Dekker, M. Bazuine, R.C. van Ham, W. van der Houven van Oordt, G. Hateboer, A.J. van der Eb, A.G. Jochemsen, MDMX: a novel p53-binding protein with some functional properties of MDM2, *EMBO J.* 15 (19) (1996) 5349–5357 <http://www.ncbi.nlm.nih.gov/pubmed/8895579>, Accessed date: 12 January 2019.
- [23] R. Gyanchandani, Y. Lin, H.-M. Lin, K. Cooper, D.P. Normolle, A. Brufsky, M. Pastuca, W. Crosson, S. Oesterreich, N.E. Davidson, R. Bhargava, D.J. Dabbs, A.V. Lee, Intratumor heterogeneity affects gene expression profile test prognostic risk stratification in early breast cancer, *Clin. Cancer Res.* 22 (21) (2016) 5362–5369.
- [24] P. Jambal, M.M. Badtke, J.C. Harrell, V.F. Borges, M.D. Post, G.E. Sollender, M.A. Spillman, K.B. Horwitz, B.M. Jacobsen, Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features, *Breast Canc. Res. Treat.* 137 (2) (2013) 431–448.
- [25] N. Tasdemir, E.A. Bossart, Z. Li, L. Zhu, M.J. Sikora, K.M. Levine, B.M. Jacobsen, G.C. Tseng, N.E. Davidson, S. Oesterreich, Comprehensive phenotypic characterization human invasive lobular carcinoma cell lines in 2D and 3D cultures, *Cancer Res.* 78 (21) (2018) 6209–6222.
- [26] C. Fellmann, T. Hoffmann, V. Sridhar, B. Hopfgartner, M. Muhar, M. Roth, D.Y. Lai, I.A.M. Barbosa, J.S. Kwon, Y. Guan, N. Sinha, J. Zuber, An optimized microRNA backbone for effective single-copy RNAi, *Cell Rep.* 5 (6) (2013) 1704–1713.
- [27] K. Lundgren, K. Holm, B. Nordenskjöld, Å. Borg, G. Landberg, Gene products of chromosome 11q and their association with CCND1 gene amplification and tamoxifen resistance in premenopausal breast cancer, *Breast Cancer Res.* 10 (5) (2008).
- [28] S.S. Kwek, R. Roy, H. Zhou, J. Climent, J.A. Martinez-Climent, J. Fridlyand, D.G. Albertson, Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis, *Oncogene* 28 (17) (2009) 1892–1903.
- [29] M. Wade, Y.C. Li, G.M. Wahl, MDM2, MDMX and p53 in oncogenesis and cancer therapy, *Nat. Rev. Canc.* 13 (2) (2013) 83–96.
- [30] Home, The cancer genome atlas - cancer genome - TCGA, <https://cancergenome.nih.gov/>, Accessed date: 9 January 2019.
- [31] D. Danovi, E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, P. de Graaf, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P.G. Pelicci, A.G. Jochemsen, J.-C. Marine, Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity, *Mol. Cell. Biol.* 24 (13) (2004) 5835–5843.
- [32] M. Christgen, P.W.B. Derksen, Lobular breast cancer: molecular basis, mouse and cellular models, *Breast Cancer Res.* 17 (1) (2015) 16.
- [33] S. Haupt, D. Buckley, J.M.B. Pang, J. Panimaya, P.J. Paul, C. Gamell, E.A. Takano, Y. Ying Lee, S. Hiddingh, T.M. Rogers, A.F.A.S. Teunisse, M.J. Herold, J.C. Marine, S.B. Fox, A. Jochemsen, Y. Haupt, Targeting Mdmx to treat breast cancers with wild-type p53, *Cell Death Dis.* 6 (7) (2015) e1821–e1821.
- [34] A. Gembarska, F. Luciani, C. Fedele, E.A. Russell, M. Dewaele, S. Villar, A. Zwolinska, S. Haupt, J. de Lange, D. Yip, J. Goydos, J.J. Haigh, Y. Haupt,

- L. Larue, A. Jochemsen, H. Shi, G. Moriceau, R.S. Lo, G. Ghanem, et al., MDM4 is a key therapeutic target in cutaneous melanoma, *Nat. Med.* 18 (8) (2012) 1239–1247.
- [35] R. Tajiri, M. Inokuchi, S. Sawada-Kitamura, H. Kawashima, R. Nakamura, T. Oyama, Y. Dobashi, A. Ooi, Clonal profiling of mixed lobular and ductal carcinoma revealed by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization, *Pathol. Int.* 64 (5) (2014) 231–236.
- [36] R.X. Song, G. Mor, F. Naftolin, R.A. McPherson, J. Song, Z. Zhang, W. Yue, J. Wang, R.J. Santen, Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol, *J. Natl. Cancer Inst.* 93 (22) (2001) 1714–1723.
- [37] M.J. Ellis, F. Gao, F. Dehdashti, D.B. Jeffe, P.K. Marcom, L.A. Carey, M.N. Dickler, P. Silverman, G.F. Fleming, A. Kommareddy, S. Jamalabadi-Majidi, R. Crowder, B.A. Siegel, Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study, *J. Am. Med. Assoc.* 302 (7) (2009) 774–780.
- [38] K. Kota, A. Brufsky, S. Oesterreich, A. Lee, Estradiol as a targeted, late-line therapy in metastatic breast cancer with estrogen receptor amplification, *Cureus* 9 (7) (2017) e1434.
- [39] S. Li, D. Shen, J. Shao, R. Crowder, W. Liu, A. Prat, X. He, S. Liu, J. Hoog, C. Lu, L. Ding, O.L. Griffith, C. Miller, D. Larson, R.S. Fulton, M. Harrison, T. Mooney, J.F. McMichael, J. Luo, et al., Endocrine-therapy-Resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts, *Cell Rep.* 4 (6) (2013) 1116–1130.
- [40] F. Menghi, F.P. Barthel, V. Yadav, M. Tang, B. Ji, Z. Tang, G.W. Carter, Y. Ruan, R. Scully, R.G.W. Verhaak, J. Jonkers, E.T. Liu, The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations, *Cancer Cell* 34 (2) (2018) 197–210 e5.
- [41] S. Nik-Zainal, H. Davies, J. Staaf, M. Ramakrishna, D. Glodzik, X. Zou, I. Martincorena, L.B. Alexandrov, S. Martin, D.C. Wedge, P. Van Loo, Y.S. Ju, M. Smid, A.B. Brinkman, S. Morganella, M.R. Aure, O.C. Lingjærde, A. Langerød, M. Ringnér, et al., Landscape of somatic mutations in 560 breast cancer whole-genome sequences, *Nature* 534 (7605) (2016) 47–54.
- [42] I. Ullah, G.M. Karthik, A. Alkodsí, U. Kjällquist, G. Stålhammar, J. Löfvrot, N.F. Martínez, J. Lagergren, S. Hautaniemi, J. Hartman, J. Bergh, Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes, *J. Clin. Investig.* 128 (4) (2018) 1355–1370.
- [43] L.R. Yates, S. Knappskog, D. Wedge, J.H.R. Farmery, S. Gonzalez, I. Martincorena, L.B. Alexandrov, P. Van Loo, H.K. Haugland, P.K. Lilleng, G. Gundem, M. Gerstung, E. Pappaemmanuil, P. Gazinska, S.G. Bhosle, D. Jones, K. Raine, L. Mudie, C. Latimer, et al., Genomic evolution of breast cancer metastasis and relapse, *Cancer Cell* 32 (2) (2017) 169–184 e7.
- [44] P.J. Miranda, D. Buckley, D. Raghu, J.M.B. Pang, E.A. Takano, R. Vijayakumaran, A.F.A.S. Teunisse, A. Posner, T. Procter, M.J. Herold, C. Gamell, J.C. Marine, S.B. Fox, A. Jochemsen, S. Haupt, Y. Haupt, MDM4 is a rational target for treating breast cancers with mutant p53, *J. Pathol.* 241 (5) (2017) 661–670.
- [45] Y. Jin, S.X. Zeng, X.-X. Sun, H. Lee, C. Blattner, Z. Xiao, H. Lu, MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2, *Mol. Cell. Biol.* 28 (4) (2008) 1218–1229.
- [46] M. Wunderlich, M. Ghosh, K. Weghorst, S.J. Berberich, MdmX represses E2F1 transactivation, *Cell Cycle* 3 (4) (2004) 472–478.
- [47] W.M. Swetzig, J. Wang, G.M. Das, Estrogen receptor alpha mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer, *Oncotarget* 7 (13) (2016) 16049–16069.
- [48] Q. Li, G. Lozano, Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy, *Clin. Cancer Res.* 19 (1) (2013) 34–41.